Scarica l'app Stockscreener
0.8918
0.21%
0.0019
Dopo l'orario di chiusura:
.86
-0.0318
-3.57%
Precedente Chiudi:
$0.8899
Aprire:
$0.87
Volume 24 ore:
398.28K
Relative Volume:
0.23
Capitalizzazione di mercato:
$6.21M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-19.66%
1M Prestazione:
+23.86%
6M Prestazione:
-89.27%
1 anno Prestazione:
-99.35%
Intervallo 1D:
$0.8649
$0.9074
Intervallo di 1 settimana:
$0.82
$0.9896
Portata 52W:
$0.5338
$143.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Nome
Cero Therapeutics Holdings Inc
Settore
Industria
Telefono
650-407-2376
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta CERO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.8918 | 6.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.86 | 126.60B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.00 | 64.75B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
639.90 | 36.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 31.40B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
102.43 | 28.98B | 2.98B | -717.57M | -264.74M | -2.9987 |
Cero Therapeutics Holdings Inc Borsa (CERO) Ultime notizie
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia
CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq
Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com
CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire
Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan
CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com
CERo Therapeutics announces up to $8M Series D financing; shares up - MSN
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com
New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com
A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com
CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com
CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire
Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan
Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News
CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX
Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX
CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World
CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga
CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com
CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire
Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia
CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa
What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister
CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq
D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Boral Capital sets Cero Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
CERo Therapeutics secures $8 million in funding for cancer therapy - Investing.com Australia
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy Development - Nasdaq
CERo Therapeutics Lands $8M Series D Funding: FDA-Cleared Cancer Trials at MD Anderson Set to Launch - Stock Titan
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing - ADVFN
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 - ADVFN
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - ADVFN
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - ADVFN
Insider Sale Alert: CERo Therapeutics Holdings Inc [CERO] – Is it Time to sell? - knoxdaily.com
CERO THERAPEUTICS HOLDINGS, INC. SEC 10-K Report - TradingView
CERO stock plunges to 52-week low of $0.64 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low of $0.64 amid market challenges - Investing.com Canada
CERo Therapeutics expands patent portfolio for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics expands patent portfolio with new US approvals By Investing.com - Investing.com South Africa
Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office - marketscreener.com
CERo Therapeutics expands patent portfolio for cancer therapy - Investing.com Australia
CERo Therapeutics expands patent portfolio with new US approvals - Investing.com
CERo Therapeutics Holdings, Inc. Announces Critical Patent - GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. - Bluefield Daily Telegraph
Cero Therapeutics Holdings Inc Azioni (CERO) Dati Finanziari
Non sono disponibili dati finanziari per Cero Therapeutics Holdings Inc (CERO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.89%
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):